Q2 2018 · —
Revenue$5.70M$5.70M −62.9% vs Q2 2017−1.5% vs Q1 2018
Net Income-$11.54M-$11.54M N/M vs Q2 2017N/M vs Q1 2018
EPS Diluted-$24.17-$24.17 N/M vs Q2 2017N/M vs Q1 2018
Operating Income-$12,088,000—
Operating Cash Flowderived-$13,945,000—
Free Cash Flowderived-$13,981,000—
Margins · derived
Operating margin-211.9%
Net margin-202.3%−190.5 pt vs Q2 2017
What the release said
No earnings release is on file for this quarter. Its figures came with the 10-Q.
Same quarter
| Metric | Q2 2018 | Q2 2017 |
|---|---|---|
| Revenue | $5.70M | $15.36M |
| Net Income | -$11.54M | -$1.81M |
| EPS Diluted | -$24.17 | -$4.07 |
The same fiscal quarter, prior years. Thaler holds no estimates to compare against.
Sutro Biopharma, Inc. · CIK 1382101 · Engraved from SEC EDGAR